Cartilage Diseases

• EMA withdrawal · 2026-04-15
  EMA Application withdrawn: Jelrix — TETEC Tissue Engineering Technologies AG

  EMA has withdrawn the Jelrix application from TETEC Tissue Engineering Technologies AG. The product targeted knee injuries and cartilage dis…

• EMA withdrawal · 2017-01-12
  EMA Withdrawn: ChondroCelect (characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins) — TiGenix N.V.

  The EMA has withdrawn ChondroCelect, a therapy using autologous cartilage cells expanded ex vivo, from the market.